Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis
Jean-Christophe Lagier, Matthieu Million, Philippe Gautret, Philippe Colson, Sébastien Cortaredona, Audrey Giraud-Gatineau, Stéphane Honoré, Jean-Yves Gaubert, Pierre-Edouard Fournier, Hervé Tissot-Dupont, Eric Chabrière, Andreas Stein, Jean-Claude Deharo, Florence Fenollar, Jean-Marc Rolain, Yolande Obadia, Alexis Jacquier, Bernard La Scola, Philippe Brouqui, Michel Drancourt, Philippe Parola, Didier Raoult, Sophie Amrane, Camille Aubry, Matthieu Bardou, Cyril Berenger, Laurence Camoin-Jau, Nadim Cassir, Claire Decoster, Catherine Dhiver, Barbara Doudier, Sophie Edouard, Stéphanie Gentile, Katell Guillon-Lorvellec, Marie Hocquart, Anthony Levasseur, Morgane Mailhe, Isabelle Ravaux, Magali Richez, Yanis Roussel, Piseth Seng, Christelle Tomei, Christine Zandotti
Travel Medicine and Infectious Disease, doi:10.1016/j.tmaid.2020.101791
Conclusion: Although this is a retrospective analysis, results suggest that early diagnosis, early isolation and early treatment of COVID-19 patients, with at least 3 days of HCQ-AZ lead to a significantly better clinical outcome and a faster viral load reduction than other treatments. Table 1 Key numbers of activities at IHU M� editerran� ee Infection (2020, February 27th -2020 May 12th). Patients tested for SARS-CoV-2 31,003 individuals including 1,277 health care workers Patients hospitalized in day-care hospital 3,525 Patients hospitalized in infectious diseases units 705 Serology SARS-CoV-2 6,000 samples tested including 643 samples from health care workers Culture 4,786 samples inoculated 1,908 SARS-CoV-2 strains isolated Genome 466 genomes sequenced and analysed Low-dose CT scan 2,218 performed Electrocardiograms 7,800 performed Serum drug dosages 1,939 hydroxychloroquine dosages
Author's note Since this analysis was completed, and as of the 11 th June, 2020, 6 more patients died including 1 patient treated with HCQ-AZ for at least 3 days and 5 in the other group, resulting in an overall 1.1% case fatality rate for the 3,737 patients included in our study.
Declaration of competing interests The authors declare no competing interests. Funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. Our group used widely available generic drugs distributed by many pharmaceutical companies.
CRediT authorship contribution statement
Appendix A. Supplementary data Supplementary data to this article can be found online at https://doi. org/10.1016/j.tmaid.2020.101791.
References
Andreani, Bideau, Duflot, In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect, Microb Pathog
Armstrong, Richez, Raoult, Simultaneous UHPLC-UV analysis of hydroxychloroquine, minocycline and doxycycline from serum samples for the therapeutic drug monitoring of Q fever and Whipple's disease, J Chromatogr B Analyt Technol Biomed Life Sci
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the treatment of covid-19 -preliminary report, N Engl J Med
Cao, Wang, Wen, A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19, N Engl J Med
Carlucci, Ahuja, Petrilli, Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients, medRxiv,
doi:10.1101/2020.05.02.20080036Charlson, Szatrowski, Peterson, Validation of a combined comorbidity index, J Clin Epidemiol
Chen, Hu, Zhang, Jiang, Han et al., Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial, medRxiv,
doi:10.1101/2020.03.22.20040758Concato, Shah, Horwitz, Randomized, controlled trials, observational studies, and the hierarchy of research designs, N Engl J Med,
doi:10.1056/NEJM200006223422507Edouard, Colson, Melenotte, Evaluating the serological status of COVID-19 patients using an indirect immunofluorescent assay,
doi:10.1101/2020.05.05.20092064Frieden, Evidence of health decision making-beyond randomized controlled trials, N Engl J Med
Gao, Tian, Yang, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends
Gautret, Lagier, Parola, Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study, Trav Med Infect Dis
Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents
Gautret, Raoult, Nullane salus extra ecclesiam, New Microbes New Infect
Geleris, Sun, Platt, Observational study of hydroxychloroquine in hospitalized patients with covid-19, N Engl J Med
Katzen, Kohn, Houk, Early oseltamivir after hospital admission is associated with shortened hospitalization: a 5-year analysis of oseltamivir timing and clinical outcomes, Clin Infect Dis
Liao, Wang, Kang, Novel coronavirus infection during the 2019-2020 epidemic: preparing intensive care units-the experience in Sichuan Province, China, Intensive Care Med
Mah� Evas, Tran, Roumier, Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data, BMJ
Middeldorp, Coppens, Van Haaps, Incidence of venous thromboembolism in hospitalized patients with COVID-19, J Thromb Haemostasis
Million, Gautret, Colson, Clinical efficacy of chloroquine derivatives in COVID-19 infection : comparative meta-analysis between the big data and the real world, New Microbes New Infect,
doi:10.1016/j.nmni.2020.100709Million, Lagier, Gautret, Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France, Trav Med Infect Dis,
doi:10.1016/j.tmaid.2020.101738Onder, Rezza, Brusaferro, Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy, JAMA,
doi:10.1001/jama.2020.4683Qin, Zhou, Hu, Dysregulation of immune response in patients with COVID-19 in Wuhan, China, Clin Infect Dis
Risch, Early outpatient treatment of symptomatic, high-risk covid-19 patients that should be ramped-up immediately as Key to the pandemic crisis, kwaa093 Am J Epidemiol,
doi:10.1093/aje/kwaa093Rosenberg, Dufort, Udo, Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state, JAMA
Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Wang, Zhang, Du, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet
Yu, Li, Chen, Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19, Sci China Life Sci,
doi:10.1007/s11427-020-1732-2Zeng, Yu, Gou, Effect of convalescent plasma therapy on viral shedding and survival in COVID-19 patients, J Infect Dis
Zhang, Sun, Feng, Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
